Banco de tejido ovárico para jóvenes con cáncer de mama

Informe preliminar de los primeros casos

  • Francisco Cóppola Universidad de la República, Facultad de Medicina, Clínica Ginecotocológica. Prof. Adjunto
  • Álvaro Domínguez Universidad de la República, Facultad de Medicina, Clínica Ginecotocológica, Prof. Adjunto. Especialista en Reproducción
  • Macarena Oliveras Ministerio de Salud Pública, Centro Hospitalario Pereira Rossell, Centro Hemato-Oncológico, Policlínica de Secuelas Reproductivas
  • Teresa Ibarra Ministerio de Salud Pública, Centro Hospitalario Pereira Rossell, Centro Hemato-Oncológico, Policlínica de Secuelas Reproductivas
Palabras clave: CRIOPRESERVACIÓN, OVARIO, NEOPLASIAS DE LA MAMA

Resumen

Introducción: el número de pacientes jóvenes con cáncer de mama parece ser mayor en Uruguay que en los promedios internacionales. Muchas de estas jóvenes no tienen hijos y la consejería en reproducción es actualmente recomendada por las sociedades científicas de referencia. En nuestro país funciona desde 2005 un programa de Preservación de la Función Ovárica ante el Cáncer, en el ámbito del Centro Hemato-Oncológico Pediátrico del Centro Hospitalario Pereira Rossell, que realiza consejería y técnicas de criopreservación de tejido ovárico destinadas a pacientes de todos los ámbitos y en forma gratuita.
Objetivos:el objetivo principal de este trabajo es presentar los primeros casos de cáncer de mama en pacientes jóvenes que ingresaron en el protocolo de criopreservación de tejido ovárico.
El objetivo secundario es difundir y lograr incorporar en la práctica clínica la derivación de las pacientes jóvenes sin hijos que reciban este diagnóstico a una consejería en reproducción.
Material y método: en el marco del protocolo previamente aprobado por la Facultad de Medicina se tomaron los primeros cinco casos de pacientes que ingresaron con diagnóstico de cáncer de mama, sin hijos jóvenes y en estadios iniciales. La extracción de tejido ovárico se realizó luego de la cirugía oncológica y antes del tratamiento complementario mediante laparoscopía. El tejido se almacenó en el Instituto Nacional de Donación y Trasplantes de Células, Tejidos y Órganos (INDYT).
Resultados: cinco pacientes de entre 26 y 35 años ingresaron al protocolo en el período mayo de 2006 a enero de 2009. Una de las pacientes falleció, comprobándose que era un estadio superior al planteado inicialmente. Las cuatro pacientes restantes están en tratamiento complementario con buena evolución y en amenorrea. Por lo tanto, no están planteados procedimientos de reimplante al momento.
Discusión y conclusiones: Uruguay cuenta, con carácter gratuito y universal, con una de las opciones disponibles para preservar tejido ovárico indemne. Procedimiento, no obstante, de carácter experimental. Sin embargo, se reciben pocas derivaciones de pacientes con cáncer de mama. La consejería en fertilidad y la derivación correspondiente es un aspecto básico y fundamental.

Citas

(1) Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55(1): 10-30.
(2) Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14(5): 1718-29.
(3) National Cancer Institute. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008. Disponible en: http://seer.cancer.gov/csr/1975_2005/. Consulta: 15 setiembre 2010.
(4) Vázquez T, Krygier G, Barrios E, Cataldi S,Vázquez A, Alonso R, et al. Análisis de sobrevida de una población con cáncer de mama y su relación con factores pronósticos: estudio de 1.311 pacientes seguidas durante 230 meses Rev Med Urug 2005; 21(2): 107-21.
(5) Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004; 100(3): 465-9.
(6) Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007; 334(7586): 194.
(7) Mueller BA, Simon MS, Deapen D, Kamineni A, Malone KE, Daling JR. Childbearing and survival after breast carcinoma in young women. Cancer 2003; 98(6): 1131-40.
(8) Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24(18): 2917-31.
(9) Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Res 2007; 9(6): 115.
(10) Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 2008; 15(1): 31-4.
(11) Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26(5):778-85. Erratum in: J Clin Oncol 2008; 26(16): 2793.
(12) Davis VJ. Female gamete preservation. Cancer 2006; 107(7 Suppl): 1690-4.
(13) Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007; 23(11): 625-31.
(14) Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006; 11(5): 422-34.
(15) Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817-26.
(16) Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360(8): 790-800.
(17) Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52(2): 365-72.
(18) Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004; 19(6): 1294-9.
(19) Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17(2): 121-55.
(20) Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008; 23(4): 863-8.
(21) Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12(9): 1055-66.
(22) Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19(2): 159-62.
(23) Center for Disease Control and Prevention (CDC). 2004 Assisted Reproductive Technology (ART) Report. Disponible en: http://ftp.cdc.gov/pub/publications/art/2004ART508.pdf. Consulta: 15 setiembre 2010.
(24) Chen CH, Zhang X, Barnes R, Confino E, Milad M, Puscheck E, et al. Relationship between peak serum estradiol levels and treatment outcome in in vitro fertilization cycles after embryo transfer on day 3 or day 5. Fertil Steril 2003; 80(1): 75-9.
(25) Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009; 169(3): 365-75.
(26) Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23(19): 4347-53.
(27) Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod 2005; 20(6): 1511-5.
(28) Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C,et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001; 22(5): 191-7.
(29) Casper RF. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 2007; 106(1-5): 71-5.
(30) Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006; 102(1-5): 71-8.
(31) Rienzi L, Martinez F, Ubaldi F, Minasi MG, Iacobelli M, Tesarik J, et al. Polscope analysis of meiotic spindle changes in living metaphase II human oocytes during the freezing and thawing procedures. Hum Reprod 2004; 19(3): 655-9.
(32) Bianchi V, Coticchio G, Fava L, Flamigni C, Borini A. Meiotic spindle imaging in human oocytes frozen with a slow freezing procedure involving high sucrose concentration. Hum Reprod 2005; 20(4): 1078-83.
(33) Gook DA, Osborn SM, Johnston WI. Cryopreservation of mouse and human oocytes using 1, 2-propanediol and the configuration of the meiotic spindle. Hum Reprod 1993; 8(7): 1101-9.
(34) Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S, Flamigni C. Human oocyte cryopreservation: new perspectives regarding oocyte survival. Hum Reprod 2001; 16(3): 411-6.
(35) Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86(1): 70-80.
(36) Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004; 82(4): 993-8.
(37) Stachecki JJ, Cohen J. An overview of oocyte cryopreservation. Reprod Biomed Online 2004; 9(2): 152-63.
(38) Practice Committee of the Society for Assisted Reproductive Technology; Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion. Fertil Steril 2007; 88(6): 1495-6.
(39) Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2006; 86(5 Suppl 1): S142-7.
(40) Parkes AS, Smith AU. Regeneration of rat ovarian tissue grafted after exposure to low temperatures. Proc R Soc Lond B Biol Sci 1953; 140(901): 455-70.
(41) Deanesly R, Parkes A. Delayed development of grafts from frozen ovarian tissue. J Endocrinol 1956; 14: 35-6.
(42) Newton H. The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Hum Reprod Update 1998; 4(3): 237-47.
(43) Hovatta O, Silye R, Krausz T, Abir R, Margara R, Trew G, et al. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hum Reprod 1996; 11(6): 1268-72.
(44) Oktay K, Nugent D, Newton H, Salha O, Chatterjee P, Gosden RG. Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue. Fertil Steril 1997; 67(3): 481-6.
(45) Pérez Campos H, Cóppola Gonzálvez F, Martínez Torena J, Afonzo Y, Domínguez A, Aguirre R, et al. Criopreservación de corteza ovárica en pacientes jóvenes con cáncer e indicación de tratamiento gonadotóxico Rev Med Urug 2007; 23(2): 99-108
(46) Royal College of Obstetricians and Gynaecologists. Storage of Ovarian and Prepubertal Testicular Tissue. Report of a Working Party. London: RCOG Press, 2000.
(47) Multidisciplinary Working Group convened by the British Fertility Society. A strategy for fertility services for survivors of childhood cancer. Hum Fértil (Camb) 2003; 6(2): A1-A39.
(48) Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004; 82(4): 993-8.
(49) FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. Ethical considerations and recommendations on oocyte and ovarian cryopreservation. FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. Int J Gynaecol Obstet 2006; 92(3): 335-6.
(50) Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugières L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 2002; 17(6): 1447-52.
(51) Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 2005; 20(12): 3539-46.
(52) Meirow D, Baum M, Yaron R, Levron J, Hardan I, Schiff E, et al. Ovarian tissue cryopreservation in hematologic malignancy: ten years' experience. Leuk Lymphoma 2007; 48(8): 1569-76.
(53) Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008; 136(6): 681-9.
(54) Radich JP. The use of PCR technology for detecting minimal residual disease in patients with leukemia. Rev Immunogenet 1999; 1(2): 265-78.
(55) Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra'anani H, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008; 23(5): 1007-13.
(56) Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol 1994; 84(3): 449-52.
(57) Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003; 289(11): 1421-4.
(58) Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 2004; 19(3): 477-80.
(59) Mancini J, Rey D, Préau M, Malavolti L, Moatti JP. Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer. Fertil Steril 2008; 90(5): 1616-2.
(60) Donnez J, Squifflet J, Van Eyck AS, Demylle D, Jadoul P, Van Langendonckt A, et al. Restoration of ovarian function in orthotopically transplanted cryopreserved ovarian tissue: a pilot experience. Reprod Biomed Online 2008; 16(5): 694-704.
(61) Kim SS, Radford J, Harris M, Varley J, Rutherford AJ, Lieberman B, et al. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod 2001; 16(10): 2056-60.
Publicado
2010-12-31
Cómo citar
1.
Cóppola F, Domínguez Álvaro, Oliveras M, Ibarra T. Banco de tejido ovárico para jóvenes con cáncer de mama. Rev. Méd. Urug. [Internet]. 31 de diciembre de 2010 [citado 30 de junio de 2022];26(4):238-45. Disponible en: http://revista.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/412
Sección
Artículos originales